DownRightNowNews
Trending
Super Typhoon Champi Becomes Strongest Storm of 2026I built an AI agent to protect my data. Then it found a hole in its guardrailsIs trust breaking down between DOJ & judges?Republicans grow more worried about a midterm blue wave as Trump’s numbers hit record lowsSI’s son shot dead, elder brother injured in GayaTripura Board Timetable 2027: When Will Class 10, 12 Date Sheets Be Out?Tamil Nadu CM Vijay Pays Tribute To Police Personnel On Police Commemoration Day #shortsPregnant woman, 33, ‘found dead on bathroom floor after partner stabbed her 60 times in face and neck in row’Super Typhoon Champi Becomes Strongest Storm of 2026I built an AI agent to protect my data. Then it found a hole in its guardrailsIs trust breaking down between DOJ & judges?Republicans grow more worried about a midterm blue wave as Trump’s numbers hit record lowsSI’s son shot dead, elder brother injured in GayaTripura Board Timetable 2027: When Will Class 10, 12 Date Sheets Be Out?Tamil Nadu CM Vijay Pays Tribute To Police Personnel On Police Commemoration Day #shortsPregnant woman, 33, ‘found dead on bathroom floor after partner stabbed her 60 times in face and neck in row’
Science

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

·1h ago
Share:PostShare

BOSTON--(BUSINESS WIRE)--AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC, an affiliate of Astellas Pharma Inc. (TSE: 4503), to discover and develop novel miniprotein-based therapeutics. Under the terms of the agreement, AI Proteins is eligible to receive over $400 million in upfront and milest

B

Businesswire

Original source

Read full story
TechnologyBusinessHealth

Related Stories

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer